Heather Ann Wakelee, MD

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

17 plans · 3 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Wakelee’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

17 of 17 plans

Sort by

Plans whose provider directory lists this clinician

Alignment Health BreathEasy (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Clarity (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Harmony (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Honor+ Plan (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health My Choice CalCare (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Silicon (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health smartHMO (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health the ONE (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
SCAN Balance (HMO C-SNP)	SCAN Health Plan	Listed	Oct 3, 2026
SCAN Classic (HMO)	SCAN Health Plan	Listed	Oct 3, 2026
SCAN MyChoice (HMO)	SCAN Health Plan	Listed	Oct 3, 2026
SCAN Strive (HMO C-SNP)	SCAN Health Plan	Listed	Oct 3, 2026
DualConnect (HMO D-SNP)	Santa Clara Family Health Plan	Listed	Sep 1, 2026

California Medical Board record

Licence A63195 · Current

Licensed to practise in California · since 1997 · expires 2027-07-31 · Johns Hopkins University School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024

See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Sort by

Every scored measure at Stanford Health Care

Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths	5.31 (4.24 to 6.37) · 8,661 cases	Worse	Jul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits	14.1 (12.7 to 15.7) · 2,191 cases	Worse	Jan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths	4.08 (1.95 to 6.21) · 5,296 cases	Better	Jul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections	0.317	Better	Oct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections	0.446	Better	Oct 2024 – Sep 2025
SSI - Colon SurgeryInfections	0.241	Better	Oct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits	0.7 (0.6 to 0.9) · 3,348 cases	Better	Jan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths	1.06 (0.45 to 1.67) · 5,374 cases	No different	Jul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths	0.86 (0.72 to 1)	No different	Jul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths	166.09 (137.88 to 194.3) · 470 cases	No different	Jul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths	1.1 · 192 cases	None	Jul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths	6.4 · 146 cases	None	Jul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths	9.7 · 253 cases	None	Jul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths	6.3 · 880 cases	None	Jul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths	10.3 · 935 cases	None	Jul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths	8.7 · 501 cases	None	Jul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths	2.1 · 7,730 cases	None	Jul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths	0.13 (0 to 0.27) · 20,799 cases	No different	Jul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths	0.28 (0.14 to 0.43) · 23,182 cases	No different	Jul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths	0.94 (0.2 to 1.68) · 5,694 cases	No different	Jul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths	2.36 (1.54 to 3.19) · 7,846 cases	No different	Jul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths	5.2 (3.76 to 6.64) · 5,603 cases	No different	Jul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths	1.38 (0.23 to 2.53) · 2,211 cases	No different	Jul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths	0.52 (0.21 to 0.83) · 19,915 cases	No different	Jul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths	3.6 · 416 cases	None	Apr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections	0.869	No different	Oct 2024 – Sep 2025
MRSA BacteremiaInfections	0.857	No different	Oct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections	0.368	No different	Oct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits	16.2 · 247 cases	None	Jul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits	20.5 · 1,021 cases	None	Jul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits	47.8 · 258 cases	None	Jul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits	-1.6 · 990 cases	None	Jul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits	20.8 · 976 cases	None	Jul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits	16.5 · 959 cases	None	Jul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits	5.2 (4.4 to 6.2) · 2,191 cases	No different	Jan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits	5.1 · 425 cases	None	Jul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits	9.6 · 158 cases	None	Jul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits	19.6 · 183 cases	None	Jul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits	12.7 (10.4 to 15.4) · 4,578 cases	No different	Jan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Sort by

Patient survey stars by topic at Stanford Health Care

Cleanliness	4
Nurse communication	4
Doctor communication	4
Communication about medicines	3
Discharge information	4
Overall hospital rating	4
Quietness	2
Recommend hospital	5

Sort by

Share of patients giving the best answer at Stanford Health Care

Room was "always" clean	75%
Nurses "always" communicated well	82%
Doctors "always" communicated well	81%
Staff "always" explained	63%
Yes, staff "did" give patients this information	89%
Yes, staff "did" give patients information about help after discharge	89%
Doctors "always" explained things so they could understand	76%
Doctors "always" listened carefully	80%
Doctors "always" treated them with courtesy and respect	87%
Patients who gave a rating of "9" or "10" (high)	79%
Staff "always" explained new medications	76%
Nurses "always" explained things so they could understand	77%
Nurses "always" listened carefully	79%
Nurses "always" treated them with courtesy and respect	88%
"Always" quiet at night	53%
"YES", patients would definitely recommend the hospital	83%
Staff "always" explained possible side effects	50%
Yes, staff "did" give patients information about possible symptoms	90%

Original Medicare doctor bills

$46,606

Medicare paid this office $46,606 for 103 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Sort by

Largest Original Medicare bills

Return visit (30+ min)	47	$15,569	$119
Long return visit (40+ min)	25	$7,356	$157
Short return visit (20+ min)	49	$6,812	$83
Return visit (30+ min)	36	$6,081	$82
Long return visit (40+ min)	18	$3,848	$120

See all 8 services

Sort by

Every Original Medicare service billed

Return visit (30+ min)	47	$15,569	$119
Long return visit (40+ min)	25	$7,356	$157
Short return visit (20+ min)	49	$6,812	$83
Return visit (30+ min)	36	$6,081	$82
Long return visit (40+ min)	18	$3,848	$120
Short return visit (20+ min)	26	$2,083	$58
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	42	$1,303	$15
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	30	$974	$15

Who their Medicare patients are

103 Original Medicare patients in 2024. Average age 73 · Women 60% · Health risk score 2.60. Above the middle of the specialty; the typical medical oncology clinician is at 2.11.

Conditions among them: Cancer 75% · High blood pressure 62% · Coronary heart disease 29% · Diabetes 23% · Chronic kidney disease 22% · Atrial fibrillation 17% · COPD 15% · Depression 15% · Heart failure 14%.

The office billed $239,922, Medicare allowed $60,489 and paid $46,606; for 577 services of 13 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Sort by

Original Medicare by year

2024	103	577	73	2.60	$239,922	$46,606
2023	114	394	74	2.44	$185,640	$34,132
2022	127	504	74	2.62	$222,057	$45,498
2021	141	557	74	2.73	$259,412	$51,083
2020	140	604	74	2.53	$196,873	$44,279
2019	165	749	73	2.83	$84,116	$57,026
2018	200	891	73	2.47	$138,111	$74,100
2017	190	731	73	2.33	$145,421	$61,113
2016	212	845	72	2.52	$211,644	$69,827
2015	220	963	72	2.27	$236,819	$77,312
2014	229	999	72	2.24	$240,070	$78,448
2013	173	856	73	2.06	$187,207	$60,846

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 3 services

Sort by

Original Medicare services billed in 2023

Return visit (30+ min)	64	$15,502	$88
Long return visit (40+ min)	30	$8,273	$131
Short return visit (20+ min)	73	$6,694	$57

2022: 3 services

Sort by

Original Medicare services billed in 2022

Return visit (30+ min)	76	$21,581	$85
Long return visit (40+ min)	49	$14,385	$127
Short return visit (20+ min)	68	$5,373	$57

2021: 3 services

Sort by

Original Medicare services billed in 2021

Return visit (30+ min)	83	$27,727	$89
Long return visit (40+ min)	52	$14,505	$134
Short return visit (20+ min)	73	$5,971	$56

2020: 5 services

Sort by

Original Medicare services billed in 2020

Return visit (30+ min)	90	$24,370	$70
Long return visit (40+ min)	44	$7,459	$99
Short return visit (20+ min)	59	$4,028	$45
New patient visit (60+ min)	16	$2,499	$156
Return visit (30+ min)	24	$2,192	$76

2019: 4 services

Sort by

Original Medicare services billed in 2019

Return visit (30+ min)	118	$31,370	$68
Long return visit (40+ min)	76	$17,475	$98
New patient visit (60+ min)	26	$3,665	$141
Short return visit (20+ min)	43	$2,600	$43

2018: 7 services

Sort by

Original Medicare services billed in 2018

Return visit (30+ min)	109	$27,935	$69
Long return visit (40+ min)	93	$25,230	$98
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	23	$6,179	$94
New patient visit (60+ min)	38	$5,432	$143
Initial hospital care with moderate level of medical decision making at least 75 minutes	13	$2,365	$182
Short return visit (20+ min)	33	$1,889	$44
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	18	$1,765	$65

2017: 4 services

Sort by

Original Medicare services billed in 2017

Long return visit (40+ min)	110	$24,960	$98
Return visit (30+ min)	109	$24,621	$67
New patient visit (60+ min)	55	$8,073	$147
Short return visit (20+ min)	21	$1,050	$40

2016: 7 services

Sort by

Original Medicare services billed in 2016

Return visit (30+ min)	103	$25,016	$65
Long return visit (40+ min)	100	$24,132	$95
New patient visit (60+ min)	53	$7,692	$145
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	12	$4,722	$93
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	14	$1,350	$61
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes	11	$1,336	$121
Short return visit (20+ min)	21	$1,003	$40

2015: 7 services

Sort by

Original Medicare services billed in 2015

Return visit (30+ min)	114	$30,641	$66
Long return visit (40+ min)	91	$18,574	$95
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	26	$9,331	$93
New patient visit (60+ min)	43	$6,329	$147
Initial hospital care with moderate level of medical decision making at least 75 minutes	16	$3,084	$181
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	18	$2,531	$65
Short return visit (20+ min)	38	$2,002	$38

2014: 10 services

Sort by

Original Medicare services billed in 2014

Return visit (30+ min)	127	$34,156	$67
Long return visit (40+ min)	77	$13,508	$94
New patient visit (60+ min)	60	$8,513	$142
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	27	$7,486	$92
Short return visit (20+ min)	57	$3,640	$42
Initial hospital care with moderate level of medical decision making at least 75 minutes	18	$3,238	$180
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	19	$2,562	$64
New patient visit (45+ min)	16	$1,850	$116
Hospital discharge day management, more than 30 minutes	11	$1,062	$97
Hospital discharge day management, 30 minutes or less	11	$720	$65

2013: 7 services

Sort by

Original Medicare services billed in 2013

Return visit (30+ min)	105	$30,558	$64
Long return visit (40+ min)	64	$11,947	$88
Short return visit (20+ min)	56	$4,915	$41
New patient visit (60+ min)	31	$4,387	$142
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	13	$3,309	$89
New patient visit (45+ min)	16	$1,631	$102
Hospital discharge day management, 30 minutes or less	11	$765	$64

Drugs they prescribed that Part D paid

$871,440

Pharmacies billed $871,440 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 78) in 2024. At or below the middle of the specialty; the typical medical oncology clinician is at 6%.

27 generic and 51 brand-name prescriptions · $871,440 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Sort by

Largest Part D drug costs

Tagrisso	32	$625,194	$19,537

Year by year

Sort by

Part D prescribing by year

2024	78	18	0% (0)	65%	$871,440
2023	67	16	0% (0)	73%	$867,946
2022	23	None	0% (0)	None	$96,592
2021	42	16	None	64%	$419,989
2020	135	35	None	53%	$1,006,990
2019	164	51	None	51%	$814,009
2018	351	76	None	None	$1,732,216
2017	481	76	None	56%	$2,473,783
2016	431	77	None	59%	$2,085,337
2015	590	93	None	42%	$1,463,386
2014	520	72	None	49%	$1,165,100
2013	564	76	2% (12)	None	$568,256

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 2 drugs

Sort by

Part D drugs prescribed in 2023

Tagrisso	25	$422,477	$16,899
Lorbrena	13	$358,734	$27,595

2021: 1 drug

Sort by

Part D drugs prescribed in 2021

Tagrisso	14	$206,161	$14,726

2020: 3 drugs

Sort by

Part D drugs prescribed in 2020

Tagrisso	40	$630,972	$15,774
Xalkori	11	$206,070	$18,734
Ondansetron	12	$126	$10

2019: 3 drugs

Sort by

Part D drugs prescribed in 2019

Afinitor Disperz	11	$184,868	$16,806
Tagrisso	12	$167,895	$13,991
Tarceva	14	$111,790	$7,985

2018: 9 drugs

Sort by

Part D drugs prescribed in 2018

Tagrisso	71	$1,114,525	$15,698
Tarceva	48	$380,270	$7,922
Alecensa	13	$189,038	$14,541
Enoxaparin	21	$8,032	$382
Dexamethasone	16	$343	$21
Prednisone	13	$120	$9
Prochlorperazine Maleate	13	$77	$6
Ondansetron	12	$62	$5
Lorazepam	13	$42	$3

2017: 11 drugs

Sort by

Part D drugs prescribed in 2017

Tarceva	115	$859,572	$7,475
Tagrisso	50	$825,057	$16,501
Alecensa	21	$311,557	$14,836
Iressa	25	$192,432	$7,697
Enoxaparin	17	$9,287	$546
Gabapentin	15	$329	$22
Prednisone	25	$200	$8
Ondansetron	16	$160	$10
Dexamethasone	17	$149	$9
Prochlorperazine Maleate	17	$116	$7
Lorazepam	19	$81	$4

2016: 11 drugs

Sort by

Part D drugs prescribed in 2016

Tarceva	104	$737,758	$7,094
Tagrisso	40	$563,041	$14,076
Alecensa	21	$275,201	$13,105
Iressa	29	$210,688	$7,265
Cometriq	11	$91,280	$8,298
Zelboraf	13	$67,145	$5,165
Enoxaparin	28	$18,379	$656
Ondansetron Odt	13	$351	$27
Dexamethasone	20	$152	$8
Prochlorperazine Maleate	17	$130	$8
Lorazepam	20	$95	$5

2015: 12 drugs

Sort by

Part D drugs prescribed in 2015

Tarceva	98	$617,771	$6,304
Xalkori	39	$519,267	$13,315
Zelboraf	12	$65,300	$5,442
Enoxaparin	37	$37,404	$1,011
Advair Diskus	11	$3,256	$296
Proair Hfa	11	$971	$88
Ondansetron Odt	32	$740	$23
Mirtazapine	23	$368	$16
Lorazepam	43	$342	$8
Ondansetron	13	$216	$17
Dexamethasone	27	$166	$6
Prochlorperazine Maleate	21	$161	$8

2014: 15 drugs

Sort by

Part D drugs prescribed in 2014

Tarceva	94	$592,067	$6,299
Xalkori	30	$355,717	$11,857
Zelboraf	11	$83,855	$7,623
Enoxaparin	22	$22,715	$1,033
Emend	17	$7,004	$412
Advair Diskus	16	$5,050	$316
Clindamycin Phosphate	11	$1,374	$125
Gabapentin	24	$467	$19
Ondansetron Odt	12	$373	$31
Mirtazapine	11	$360	$33
Levothyroxine	22	$256	$12
Dexamethasone	22	$162	$7
Lorazepam	28	$153	$5
Ondansetron	14	$124	$9
Prochlorperazine Maleate	17	$117	$7

2013: 16 drugs

Sort by

Part D drugs prescribed in 2013

Tarceva	67	$366,340	$5,468
Viread	12	$10,320	$860
Advair Diskus	37	$10,210	$276
Clindamycin Phosphate	17	$1,324	$78
Colcrys	11	$845	$77
Proair Hfa	12	$558	$46
Ondansetron Odt	17	$557	$33
Mirtazapine	14	$280	$20
Dexamethasone	25	$224	$9
Ondansetron	13	$220	$17
Prochlorperazine Maleate	25	$181	$7
Citalopram Hbr	18	$176	$10
Gabapentin	12	$153	$13
Metoclopramide	12	$118	$10
Lorazepam	16	$91	$6
Prednisone	13	$72	$6

Money from drug and device companies

$22,236 in 2025

Sort by

Industry payments by year

2025	7	15	$10,567	$22,236
2024	6	23	$8,198	$16,542
2023	6	21	$1,081	$1,700
2022	2	2	None	$140
2021	1	1	$2,500	$2,500
2020	3	3	$5,813	$5,813
2019	10	17	$8,999	$9,904

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Sort by

Payments by company

Chugai Pharmaceutical Co.	None	$15,674	3 payments Travel · 2025-11-04 · $230 Travel · 2025-11-04 · $11,003 Consulting · 2025-11-04 · $4,442
BeOne Medicines USA	None	$4,125	3 payments Consulting · 2025-11-14 · $750 Consulting · 2025-06-27 · $2,250 Consulting · 2025-04-18 · $1,125
AstraZeneca UK	None	$1,241	2 payments Consulting · 2025-11-14 · $1,200 Meals · 2025-10-18 · $41
GlaxoSmithKline	None	$852	3 payments Meals · 2025-09-07 · $52 Consulting · 2025-07-10 · $400 Consulting · 2025-05-19 · $400
AstraZeneca Pharmaceuticals LP	None	$156	2 payments Meals · 2025-10-10 · $135 Meals · 2025-01-25 · $21
Daiichi Sankyo	Enhertu	$116	1 payment Meals for Enhertu · 2025-09-20 · $116

See all 15 published payments

Sort by

Every published payment

BeOne Medicines USA	Consulting · 2025-11-14	None	$750
AstraZeneca UK	Consulting · 2025-11-14	None	$1,200
Chugai Pharmaceutical Co.	Travel · 2025-11-04	None	$230
Chugai Pharmaceutical Co.	Travel · 2025-11-04	None	$11,003
Chugai Pharmaceutical Co.	Consulting · 2025-11-04	None	$4,442
AstraZeneca UK	Meals · 2025-10-18	None	$41
AstraZeneca Pharmaceuticals LP	Meals · 2025-10-10	None	$135
Daiichi Sankyo	Meals · 2025-09-20	Enhertu	$116
GlaxoSmithKline	Meals · 2025-09-07	None	$52
GlaxoSmithKline	Consulting · 2025-07-10	None	$400
BeOne Medicines USA	Consulting · 2025-06-27	None	$2,250
GlaxoSmithKline	Consulting · 2025-05-19	None	$400
BeOne Medicines USA	Consulting · 2025-04-18	None	$1,125
Janssen Biotech	Meals · 2025-03-24	Rybrevant	$71
AstraZeneca Pharmaceuticals LP	Meals · 2025-01-25	None	$21

See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $16,542

Sort by

Payments by company in 2024

Chugai Pharmaceutical Co.	None	$13,837	4 payments Consulting · 2024-10-31 · $1,077 Travel · 2024-10-30 · $581 Travel · 2024-10-30 · $7,239 Consulting · 2024-10-30 · $4,940
Pfizer	None	$1,491	14 payments Honoraria · 2024-10-23 · $608 Meals · 2024-09-17 · $2 Travel · 2024-09-17 · $10 Meals · 2024-09-16 · $2 Travel · 2024-09-16 · $10 Meals · 2024-09-15 · $2 Travel · 2024-09-15 · $10 Honoraria · 2024-07-03 · $774 Meals · 2024-06-04 · $5 Travel · 2024-06-04 · $29 Meals · 2024-06-04 · $3 Meals · 2024-06-03 · $5 Travel · 2024-06-03 · $29 Meals · 2024-06-02 · $5
GlaxoSmithKline	None	$800	1 payment Consulting · 2024-11-21 · $800
AstraZeneca Pharmaceuticals LP	Imfinzi	$270	2 payments Meals · 2024-10-04 · $135 Meals for Imfinzi · 2024-05-30 · $135
AstraZeneca UK	None	$89	1 payment Meals · 2024-09-07 · $89
Genentech USA	Alecensa	$55	1 payment Meals for Alecensa · 2024-01-20 · $55

2023: $1,700

Sort by

Payments by company in 2023

Seagen	None	$1,167	13 payments Consulting · 2023-11-30 · $308 Travel · 2023-10-24 · $9 Meals · 2023-10-24 · $1 Meals · 2023-10-24 · $1 Travel · 2023-10-23 · $15 Meals · 2023-10-23 · $1 Travel · 2023-10-22 · $15 Meals · 2023-10-22 · $1 Consulting · 2023-10-03 · $773 Meals · 2023-09-12 · $8 Travel · 2023-09-12 · $16 Travel · 2023-09-11 · $12 Meals · 2023-09-11 · $8
AstraZeneca Pharmaceuticals LP	None	$268	2 payments Meals · 2023-12-02 · $135 Meals · 2023-10-25 · $133
Genentech USA	Tecentriq	$116	1 payment Meals for Tecentriq · 2023-01-21 · $116
AstraZeneca UK	Tagrisso	$88	2 payments Meals for Tagrisso · 2023-10-20 · $70 Travel for Tagrisso · 2023-10-20 · $18
Merck Sharp & Dohme	Keytruda	$32	2 payments Meals for Keytruda · 2023-10-22 · $18 Meals for Keytruda · 2023-10-21 · $13
E.R. Squibb & Sons L.L.C.	None	$30	1 payment Meals · 2023-09-30 · $30

2022: $140

Sort by

Payments by company in 2022

AstraZeneca Pharmaceuticals LP	Tagrisso	$123	1 payment Meals for Tagrisso · 2022-11-11 · $123
Pfizer	Lorbrena	$18	1 payment Education for Lorbrena · 2022-10-19 · $18

2021: $2,500

Sort by

Payments by company in 2021

F. Hoffmann-La Roche AG	None	$2,500	1 payment Consulting · 2021-07-27 · $2,500

2020: $5,813

Sort by

Payments by company in 2020

AstraZeneca Pharmaceuticals LP	Tagrisso	$3,450	1 payment Consulting for Tagrisso · 2020-06-17 · $3,450
Blueprint Medicines	None	$1,463	1 payment Honoraria · 2020-06-09 · $1,463
Helsinn Healthcare SA	None	$900	1 payment Consulting · 2020-02-18 · $900

2019: $9,904

Sort by

Payments by company in 2019

Novartis Pharmaceuticals	Ilaris	$4,033	4 payments Consulting for Ilaris · 2019-10-10 · $3,750 Meals for Ilaris · 2019-10-10 · $70 Meals for Inc280 · 2019-10-10 · $87 Meals · 2019-06-01 · $125
Daiichi Sankyo	None	$1,670	3 payments Consulting · 2019-09-30 · $1,563 Travel · 2019-09-07 · $91 Meals · 2019-09-07 · $17
Janssen Global Services	None	$1,550	1 payment Consulting · 2019-04-23 · $1,550
Helsinn Healthcare SA	None	$1,463	1 payment Consulting · 2019-11-10 · $1,463
F. Hoffmann-La Roche AG	Tecentriq	$674	2 payments Paid to speak or teach for Tecentriq · 2019-12-31 · $226 Paid to speak or teach for Tecentriq · 2019-12-31 · $448
Genentech	Tecentriq	$187	1 payment Meals for Tecentriq · 2019-10-12 · $187
Genentech USA	Avastin	$127	1 payment Meals for Avastin · 2019-06-01 · $127
Merck Sharp & Dohme	Keytruda	$110	2 payments Meals for Keytruda · 2019-07-26 · $35 Meals for Keytruda · 2019-06-03 · $75
AstraZeneca UK	Tagrisso	$61	1 payment Meals for Tagrisso · 2019-09-28 · $61
AstraZeneca Pharmaceuticals LP	None	$31	1 payment Meals · 2019-04-13 · $31

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Sort by

Research payments by company and study

Merck Sharp & Dohme Corporation · A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab Mk-3475 As Neoadjuvant,Adjuvant Therapy for Participants With Resectable Stage II, Iiia, and Resectable Iiib T3-4n2 Non-Small Cell Lung Cancer Nsclc Keynote-671 · 2021	Their institution	$315,871
Genentech, Inc. · Tiragolumab Tecentriq Vs Durvalumab in Unresectable Stage III Nsclc · 2025	Their institution	$232,271
Genentech, Inc. · Ph III Open Label Study Atezo Vs Bsc Following Adjuvant Chemo in Stage Ib Iiia Nsclc · 2024	Their institution	$228,554
Merck Sharp & Dohme Corporation · An Open Label, Single Arm, Phase 1b,2 Study To Evaluate Thesafety and Efficacy of Grapiprant Ary-007 in Combination Withpembrolizumab in Patients With Advanced Or Metastaticpost-Pd-1,L1 Non-Small Cell Lung Cancer Nsclcadenocarcinoma · 2019	Their institution	$162,000
Merck Sharp & Dohme Corporation · A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab Mk-3475 As Neoadjuvant,Adjuvant Therapy for Participants With Resectable Stage II, Iiia, and Resectable Iiib T3-4n2 Non-Small Cell Lung Cancer Nsclc Keynote-671 · 2020	Their institution	$158,301
Merck Sharp & Dohme Corporation · An Open Label, Single Arm, Phase 1b,2 Study To Evaluate the Safety and Efficacy of Grapiprant Ary-007 in Combination With Pembrolizumab in Patients With Advanced Or Metastatic Post-Pd-1,L1 Non-Small Cell Lung Cancer Nsclc Adenocarcinoma · 2020	Their institution	$108,000
Clovis Oncology, Inc. · Study To Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (Co-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (Egfr) in Non-Small Cell Lung Cancer (Nsclc) Patients · 2019	Their institution	$101,040
PFIZER INC. · Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced Or Metastatic Disease in Solid Tumors · 2024	Their institution	$89,304
Genentech, Inc. · Ph III Open Label Study Atezo Vs Bsc Following Adjuvant Chemo in Stage Ib Iiia Nsclc · 2019	Their institution	$87,378
Merck Sharp & Dohme LLC · A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab Mk-3475 As Neoadjuvant,Adjuvant Therapy for Participants With Resectable Stage II, Iiia, and Resectable Iiib T3-4n2 Non-Small Cell Lung Cancer Nsclc Keynote-671 · 2022	Their institution	$57,894
AstraZeneca UK Limited · A Phase II, Open-Label, Single-Arm Study of Osimertinib As Induction Therapy Prior To Crt in Patients With Epidermal Growth Factor Receptor (Egfr) Mutation-Positive, Stage III, Unresectable Non-Small Cell Lung Cancer · 2025	Their institution	$50,815
Helsinn Healthcare SA · Phase I/II Study of the Selective Ret Inhibitor Tas0953/Hm06 in Patients With Advanced Solid Tumors With Ret Gene Abnormalities · 2023	Their institution	$37,700
Merck Sharp & Dohme LLC · A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab Mk-3475 As Neoadjuvant,Adjuvant Therapy for Participants With Resectable Stage II, Iiia, and Resectable Iiib T3-4n2 Non-Small Cell Lung Cancer Nsclc Keynote-671 · 2024	Their institution	$36,505
Seagen Inc. · Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With A Safety Run-in of A Dose-Dense Regimen · 2023	Their institution	$35,008
E.R. Squibb & Sons, L.L.C. · Phase III Nsclc 1l, Sq Anti-Pd-1 Vs Platinum Doublet (Pdl-1 +) - An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator'S Choice Chemotherapy As First-Line Therapy for Stage IV Or Recurrent Pd-L1+ Non-Small Cell Lung Cancer · 2023	Their institution	$31,041
Merck Sharp & Dohme Corporation · A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab Mk-3475 As Neoadjuvant,Adjuvant Therapy for Participants With Resectable Stage Iib Or Iiia Non-Small Cell Lung Cancer Nsclc Keynote-671 · 2019	Their institution	$30,431
Genentech, Inc. · Ph III Open Label Study Atezo Vs Bsc Following Adjuvant Chemo in Stage Ib Iiia Nsclc · 2023	Their institution	$30,093
Genentech, Inc. · Tiragolumab Tecentriq Vs Durvalumab in Unresectable Stage III Nsclc · 2024	Their institution	$29,958
Roche Products Limited · Ph 1b Apdl Mek in Pts W Solid Tumors · 2020	Their institution	$28,095
Genentech, Inc. · Tiragolumab Tecentriq Vs Durvalumab in Unresectable Stage III Nsclc · 2021	Their institution	$25,250
Seagen Inc. · Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With A Safety Run-in of A Dose-Dense Regimen · 2020	Their institution	$24,733
AstraZeneca Pharmaceuticals LP · A Phase 1, 2 Study To Evaluate the Safety, Tolerability, and Pharmacokinetics of Medi4736 in Subjects With Advanced Solid Tumors · 2020	Their institution	$24,100
Helsinn Healthcare SA · Phase I/II Study of the Selective Ret Inhibitor Tas0953/Hm06 in Patients With Advanced Solid Tumors With Ret Gene Abnormalities · 2022	Their institution	$22,349
E.R. Squibb & Sons, L.L.C. · Phase III Nsclc 1l, Sq Anti-Pd-1 Vs Platinum Doublet Pdl-1 · 2020	Their institution	$16,394
Merck Sharp & Dohme Corporation · A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab Mk-3475 As Neoadjuvant,Adjuvant Therapy for Participants With Resectable Stage II, Iiia, and Resectable Iiib T3-4n2 Non-Small Cell Lung Cancer Nsclc Keynote-671 · 2019	Their institution	$16,239
Genentech, Inc. · Ph III Open Label Study Atezo Vs Bsc Following Adjuvant Chemo in Stage Ib Iiia Nsclc · 2022	Their institution	$11,446
Merck Sharp & Dohme LLC · A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab Mk-3475 As Neoadjuvant,Adjuvant Therapy for Participants With Resectable Stage II, Iiia, and Resectable Iiib T3-4n2 Non-Small Cell Lung Cancer Nsclc Keynote-671 · 2023	Their institution	$11,084
Genentech, Inc. · Ph III Open Label Study Atezo Vs Bsc Following Adjuvant Chemo in Stage Ib Iiia Nsclc · 2025	Their institution	$7,536
AstraZeneca Pharmaceuticals LP · A Phase 1, 2 Study To Evaluate the Safety, Tolerability, and Pharmacokinetics of Medi4736 in Subjects With Advanced Solid Tumors · 2019	Their institution	$7,258
Seagen Inc. · Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced Or Metastatic Disease in Solid Tumors · 2023	Their institution	$6,670
Merck Sharp & Dohme LLC · A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab Mk-3475 As Neoadjuvant,Adjuvant Therapy for Participants With Resectable Stage II, Iiia, and Resectable Iiib T3-4n2 Non-Small Cell Lung Cancer Nsclc Keyn · 2025	Their institution	$6,481
Novartis Pharmaceuticals Corporation · Phase Ib Multicenter Open Label Study of Pdr001 in Combination With Platinum Doublet Chemotherapy in Pd L1 Unselected, Metastatic Nsclc Patients · 2020	Their institution	$5,095
Seagen Inc. · Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With A Safety Run-in of A Dose-Dense Regimen · 2021	Their institution	$4,929
Genentech, Inc. · Ph III Open Label Study Atezo Vs Bsc Following Adjuvant Chemo in Stage Ib Iiia Nsclc · 2020	Their institution	$3,555
F. Hoffmann-La Roche AG · Association of Baseline Systemic Corticosteroid Use With Short- and Long-Term Outcomes in Patients With Advanced Non-Small Cell Lung Cancer, Melanoma, Or Urothelial Carcinoma Receiving Cancer Immunotherapy in Real-World US Oncology Practice · 2020	This clinician	$3,258
Genentech, Inc. · Ph III Open Label Study Atezo Vs Bsc Following Adjuvant Chemo in Stage Ib Iiia Nsclc · 2021	Their institution	$3,122
Roche Products Limited · Ph 1b Apdl Mek in Pts W Solid Tumors · 2019	Their institution	$2,964
AstraZeneca UK Limited · A Phase II, Open-Label, Single-Arm Study of Osimertinib As Induction Therapy Prior To Crt in Patients With Epidermal Growth Factor Receptor (Egfr) Mutation-Positive, Stage III, Unresectable Non-Small Cell Lung Cancer · 2024	Their institution	$2,803
F. Hoffmann-La Roche AG · Ph III Open Label Study Atezo Vs Bsc Following Adjuvant Chemo in Stage Ib Iiia Nsclc · 2024	This clinician	$2,673
E.R. Squibb & Sons, L.L.C. · Phase III Nsclc 1l, Sq Anti-Pd-1 Vs Platinum Doublet (Pdl-1 +) - An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator'S Choice Chemotherapy As First-Line Therapy for Stage IV Or Recurrent Pd-L1+ Non-Small Cell Lung Cancer · 2024	Their institution	$2,560
Seagen Inc. · Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With A Safety Run-in of A Dose-Dense Regimen · 2022	Their institution	$2,300
Seagen Inc. · Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced Or Metastatic Disease in Solid Tumors · 2021	Their institution	$1,592
F. Hoffmann-La Roche AG · Association of Baseline Systemic Corticosteroid Use With Time To Next Treatment in Patients With Advanced Melanoma, Non-Small Cell Lung Cancer Or Urothelial Cancer Receiving Cancer Immunotherapy in US Clinical Practice · 2020	This clinician	$1,402
F. Hoffmann-La Roche AG · A Phase III, Open-Label, Randomized Study To Investigate the Efficacy and Safety of Atezolizumab Anti-Pd-L1 Antibody Compared With Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in Patients With Completely Resected Stage Ib-Iiia Non-Small Cell Lung Cancer · 2022	This clinician	$1,295
E.R. Squibb & Sons, L.L.C. · Phase III Nsclc 1l, Sq Anti-Pd-1 Vs Platinum Doublet Pdl-1 · 2019	Their institution	$1,282
Genentech, Inc. · Apdl1 Phase II in Pd L1 Positive Nsclc Pts · 2019	Their institution	$972
F. Hoffmann-La Roche AG · Ph III Open Label Study Atezo Vs Bsc Following Adjuvant Chemo in Stage Ib Iiia Nsclc · 2025	This clinician	$860
Pharmacyclics LLC, An AbbVie Company · Pcyc-1135-CA · 2020	Their institution	$640
F. Hoffmann-La Roche AG · Impower010 5-Y Subgroup Analysis and Relapse Patterns: Phase 3 Study of Atezolizumab Vs Bsc in Stage II-Iiia Nsclc · 2024	This clinician	$533
F. Hoffmann-La Roche AG · Association of Baseline Systemic Corticosteroid Cs Use With Time To Next Treatment Ttnt in Advanced Nsclc, Melanoma and Urothelial Cancer Patients Treated With Cancer Immunotherapy Cit in Real World US-Based Oncology Settings · 2020	This clinician	$450
Seagen Inc. · Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced Or Metastatic Disease in Solid Tumors · 2020	Their institution	$398
Merck Sharp & Dohme Corporation · A Phase III, Multicenter, Randomized Study To Evaluate Mk 1308a Co-Formulated Mk 1308,Mk 3475 Versus Chemotherapy As Adjuvant Therapy Following Surgery in Participants With Microsatellite Instability-High Msi-H Or Mismatch Repair Deficient Dmmr High Risk Stage III Colorectal Cancer Mk 1308a-007 Aim-High · 2021	Their institution	$344
Amgen Inc. · Amg 820 - in Colorectal; Pancreatic; and Nsclc · 2019	Their institution	$52
F. Hoffmann-La Roche AG · Tiragolumab Tecentriq Vs Durvalumab in Unresectable Stage III Nsclc · 2025	This clinician	$1

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score: 76.5 / 100; Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI: 1720137094
Licence: CA A63195California A63195: Current · expires 2027-07-31
Trained: Johns Hopkins University School of Medicine, 1996
Group: Stanford Health Care
Video visits: Lists video visits
Gender: Female

More record details

Sole proprietor: No
Taxonomy: Medical oncology (207RX0202X)
Mailing address: 2260 Saint Francis Dr, Palo Alto, CA, 94303
NPI first listed: 2007-01-09
NPI last updated: 2024-04-12
NPI record certified: 2024-04-12

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 875 Blake Wilbur Dr, Stanford, CA, 94305